Furthermore, treatment with anti-IL-1β antibodies resulted in both inhibition of the IL-1β response and remission of clinical characteristics of steroid-resistant asthma, while IL-1β administration led to the restoration of these characteristics [131]. The gene discussed is IL1B; the disease is asthma.